Vitamin D and HbA1c Levels in Diabetic Patients With CKD
Association Between Serum 25-hydroxyvitamin D Levels and Glycated Haemoglobin in Diabetic Patients With Chronic Kidney Disease
1 other identifier
observational
100
0 countries
N/A
Brief Summary
The purpose of this study is to determine the association between serum 25-hydroxyvitamin D and HbA1c levels in diabetic patients with chronic kidney disease. The investigators hypothesized that serum 25-hydroxyvitamin D levels were negatively correlated with HbA1c levels.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2015
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2016
CompletedFirst Submitted
Initial submission to the registry
September 9, 2016
CompletedFirst Posted
Study publicly available on registry
September 20, 2016
CompletedSeptember 20, 2016
September 1, 2016
10 months
September 9, 2016
September 14, 2016
Conditions
Outcome Measures
Primary Outcomes (2)
25-hydroxyvitamin D levels
The unit of measure was nmol/L. The detection limit of the device was \<10 nmol/L. A mean value of 5 nmol/L were taken for results reported as \<10nmol/L.
Within 2 weeks from enrolment
HbA1c levels
The unit of measure was percentage (using NGSP standarization).
Within 2 weeks from enrolment
Eligibility Criteria
Patients who attended specialized diabetic, renal, and general outpatient clinics in the University of Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia.
You may qualify if:
- eGFR 15-59 ml/min/1.73m2
- age ≥ 18 years old
- able to provide informed consent
You may not qualify if:
- active infections
- autoimmune diseases
- malignancies
- on immunosuppressive therapy
- on vitamin D supplements
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ng Yong Muhlead
- University of Malayacollaborator
- Malaysian Society of Nephrologycollaborator
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yong Muh Ng, MMed
University of Malaya
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Dr
Study Record Dates
First Submitted
September 9, 2016
First Posted
September 20, 2016
Study Start
September 1, 2015
Primary Completion
July 1, 2016
Study Completion
July 1, 2016
Last Updated
September 20, 2016
Record last verified: 2016-09
Data Sharing
- IPD Sharing
- Will share
A dataset of participants' clinical characteristics and biochemical tests result. The data was obtained directly from the participants and via Laboratory Information System. It is ready for submission.